3. Movilizaciones obreras de la industria ferroviaria en las primeras
3.2. Nacimiento y desarrollo del Ferrocarril de Girardot
Table 1: Patient baseline characteristics
All patients: n (%) 42 (100%)
Male 30 (71.4%)
Female 12 (28.6%)
Age, years: median (range) 62 (44 – 82)
ECOG performance status: median (range) 0 (0–2)
0 31 (73.8%)
1 7 (16.7%)
2 4 (9.5%)
Site of primary tumor: n (%) 42 (100%)
small intestine 23 (54.8%) pancreas 9 (21.4%) lung 1 (2.4%) colon 5 (11.9%) unknown 4 (9.5%) Histology: n (%) 42 (100%) Carcinoid 33 (78.6%) Islet cell 6 (14.3%) Insulinoma 2 (4.8%) atypical 1 (2.4%) Prior treatment: n (%) Surgery 38 (90.5%) TACE 18 (42.9%) Chemotherapy 18 (42.9%) Interferon alpha 8 (19.0%) Octreotide 23 (54.8%)
Radionuclide therapy (DOTA-TATE) 4 (9.5%)
RFA 3 (7.1%)
Radiation 2 (4.8%)
Percutaneous Ethanol Injection 2 (4.8%) Surgery and sytemic therapy 36 (85.7%)
Surgery and TACE 12 (28.5 %)
Surgery, TACE and systemic therapy 12 (28.5 %) Time from primary NET diagnosis to radioembolization,
months
Median (range) 27.4 (3.4 – 250.6)
Mean (Standard deviation) 51.1 (59.5) Time from NETLM diagnosis to radioembolization,
months
Median (range) 23.6 (3 – 209.9)
Mean (Standard deviation) 40.9 (50)
Diagnosis of primary NET and NETLM: n (%)
Metachronous 8 Synchronous 34 Tumor volume n = 42 < 25 8 19% 26 - 50% 28 67% >50 % 6 14%
Table 2: Treatment characteristics Hepato-pulmonary shunting, %
Median (range) 5.58% (1.9 – 11.2%)
Target treatment volume; n (%)
Right lobe 17 (40.5%)
Left lobe 8 (19.0%)
Whole liver 24 (57.1%)
Retreatment of target volume: n (%) 7 (16.7%) 2 treatments (median: 23.7 months/Min. 18.3
months/Max. 28.9 months) 6 (14.3%)
3 treatments (1. retreatment after 21.3 months,
2. retreatment after 14.8 months) 1 (2.4%) Activity (90Y) delivered: GBq
Median (range) 1.57 (0.63 – 2.36)
Mean (Standard Deviation) 1.63 (0.49)
Percent of planned 90Y delivered: %
Median (range) 99.2% (76.9 – 108.3)
Table 3: Imaging follow-up using RECIST-criteria at 3 months follow-up RECIST (3 months) n=40 progressive disease 2,5 % stable disease 75 % partial response 22,5 % complete remission 0 %
Table 4. Acute and delayed toxicities by Common Terminology Criteria for Adverse Events version 3.0..
CTCAE Grade: n (%)
Grade 0 Grade 1 Grade 2 Grade >3
Fatique 26 12 4 0 Nausea 28 7 7 0 Abdominal pain 13 6 23 0 Vomiting 37 3 2 0 Diarrhea 41 1 0 0 Fever 18 18 6 0 Gastric ulcer 38 3 1 0
Table 5. Clinical symptoms
Clinical symptoms before radioembolization: n (%) 42
Symptomatic 38 (90.5%)
Asymptomatic 4 (9.5%)
Clinical symptoms after radioembolization: n (%) 38
Improved 36 (94.7%)
Table 6: No significant (p > 0.5) changes of all listed laboratory data 3 months after radioembolization could be observed.
Bilirubin mg/dl GOT U/l
baseline follow-up baseline follow-up
Median 0.6 0.7 34 52
SD 0.2 0.3 28 26
Min. 0.2 0.4 16 30
Max. 1.2 1.5 68 122
GPT U/l alkaline phosphatase U/l
baseline follow-up baseline follow-up
Median 33 55 152 245
SD 23 26 96 85
Min. 12 9 58 128
Max. 140 114 441 449
LDH U/l Gamma-glutamyl transpeptidase
baseline follow-up baseline follow-up
Median 216 209 158 354
SD 68 45 308 309
Min. 126 142 14 75
Max. 441 291 1292 1350
Cholinesterase Whole Protein
baseline follow-up baseline follow-up
Median 7 6.8 7.2 7.2
SD 1.3 1 0.7 0.5
Min. 3.7 5.5 5.5 6.5
Figure 1:
The mediandecrease of tumor marker levels was 54.8% (Chromoganin A) and 37.3% (Serotonin).
baseline follow‐up
Figure 2:
a b
c d
a + b) T1w 3D-GRE imaging with arterial contrast enhancement and HASTE-sequence of the liver, baseline scan. A hypervascular, centrally necrotic neuroendocrine tumor is depicted in the right liver lobe.
c+d) Follow-up scan after 3 months shows a significant decrease in size and vascularization after radioembolization.
Conflicts of Interest Notification:
Abrams, R. A., D. King, et al. (1987). "Objective response of malignant carcinoid to radiation therapy." Int J Radiat Oncol Biol Phys 13(6): 869-873. Akerstrom, G., P. Hellman, et al. (2005). "Management of midgut carcinoids." J Surg Oncol 89(3): 161-169.
Albrecht, T. (2008). "[HCC screening]." Radiologe 48(1): 33-38.
Bloomston, M., O. Binitie, et al. (2002). "Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy." Am Surg 68(9): 827-831.
Bosch, F. X., J. Ribes, et al. (2005). "Epidemiology of hepatocellular carcinoma." Clin Liver Dis 9(2): 191-211, v.
Brown, K. T., B. Y. Koh, et al. (1999). "Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms." J Vasc Interv Radiol 10(4): 397-403.
Bruix, J. and M. Sherman (2005). "Management of hepatocellular carcinoma." Hepatology 42(5): 1208-1236.
Bruix, J., M. Sherman, et al. (2001). "Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver." J Hepatol 35(3): 421-430.
Buscarini, E., A. Savoia, et al. (2005). "Radiofrequency thermal ablation of liver tumors." Eur Radiol 15(5): 884-894.
Buscarini, L., E. Buscarini, et al. (1999). "Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma." Ultraschall Med 20(2): 47-53. Buscarini, L., E. Buscarini, et al. (2001). "Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results." Eur Radiol 11(6): 914-921.
Camma, C., F. Schepis, et al. (2002). "Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials." Radiology 224(1): 47-54.
Cao, C. Q., T. D. Yan, et al. "Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases." Br J Surg 97(4): 537-543.
Capurso, G., R. Bettini, et al. "Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review." Neuroendocrinology.
Carr, B. I. (2004). "Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients." Liver Transpl 10(2 Suppl 1): S107-110.
Chakravarthy, A. and R. A. Abrams (1995). "Radiation therapy in the management of patients with malignant carcinoid tumors." Cancer 75(6): 1386-1390.
Chamberlain, R. S., D. Canes, et al. (2000). "Hepatic neuroendocrine metastases: does intervention alter outcomes?" J Am Coll Surg 190(4): 432- 445.
Chen, H., J. M. Hardacre, et al. (1998). "Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?" J Am Coll Surg 187(1): 88-92; discussion 92-83.
Clasen, S. and P. L. Pereira (2007). "[Combined therapies including interventional radiology]." Radiologe 47(12): 1072, 1074-1082.
Coldwell, D. M. and P. E. Sewell (2005). "The expanding role of interventional radiology in the supportive care of the oncology patient: from diagnosis to therapy." Semin Oncol 32(2): 169-173.
Delcore, R. and S. R. Friesen (1994). "Gastrointestinal neuroendocrine tumors." J Am Coll Surg 178(2): 187-211.
Duffaud, F. and P. Therasse (2000). "[New guidelines to evaluate the response to treatment in solid tumors]." Bull Cancer 87(12): 881-886.
Dupuy, D. E. and S. N. Goldberg (2001). "Image-guided radiofrequency tumor ablation: challenges and opportunities--part II." J Vasc Interv Radiol 12(10): 1135-1148.
El-Serag, H. B., J. A. Davila, et al. (2003). "The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update." Ann Intern Med 139(10): 817-823.
Eriksson, B. K., E. G. Larsson, et al. (1998). "Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors." Cancer 83(11): 2293- 2301.
Gaitan-Gaitan, A., W. D. Rider, et al. (1975). "Carcinoid tumor-cure by irradiation." Int J Radiat Oncol Biol Phys 1(1-2): 9-13.
Geschwind, J. F., D. E. Ramsey, et al. (2003). "Chemoembolization of hepatocellular carcinoma: results of a metaanalysis." Am J Clin Oncol 26(4): 344-349.
Gray, B., G. Van Hazel, et al. (2001). "Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer." Ann Oncol 12(12): 1711-1720. Gupta, S., M. M. Johnson, et al. (2005). "Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival." Cancer 104(8): 1590-1602.
Hibi, T., T. Sano, et al. (2007). "Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan." Jpn J Clin Oncol 37(2): 102-107. Jakobs, T. F., R. T. Hoffmann, et al. (2008). "[Therapy response of liver tumors after selective internal radiation therapy]." Radiologe 48(9): 839-849. Jakobs, T. F., R. T. Hoffmann, et al. (2007). "[Developments and perspectives in radioablative techniques]." Radiologe 47(12): 1083-1088.
Jemal, A., F. Bray, et al. (2011). "Global cancer statistics." CA Cancer J Clin 61(2): 69-90.
Kagawa, T., J. Koizumi, et al. (2010). "Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection." Cancer 116(15): 3638-3644.
Keane, T. J., W. D. Rider, et al. (1981). "Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor." Int J Radiat Oncol Biol Phys 7(11): 1519-1521.
Kennedy, A., S. Nag, et al. (2007). "Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium." Int J Radiat Oncol Biol Phys 68(1): 13-23.
Kennedy, A. S., W. A. Dezarn, et al. (2008). "Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y- microspheres: early results in 148 patients." Am J Clin Oncol 31(3): 271-279. Kettenbach, J., M. Blum, et al. (2004). "[Percutaneous radiofrequency ablation of liver cell carcinoma: a current overview]." Radiologe 44(4): 330-338.
Kim, J. H., H. J. Won, et al. (2011). "Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone." Ann Surg Oncol 18(6): 1624-1629. Kim, J. W., J. H. Kim, et al. (2011). "Hepatocellular carcinomas 2-3cm in diameter: Transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone." Eur J Radiol.
King, J., R. Quinn, et al. (2008). "Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases." Cancer 113(5): 921-929.
Kirikoshi, H., S. Saito, et al. (2009). "Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma." Hepatol Res 39(6): 553-562.
Kress, O., H. J. Wagner, et al. (2003). "Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single- center analysis." Digestion 68(2-3): 94-101.
Lencioni, R., D. Cioni, et al. (2001). "Combination of interventional therapies in hepatocellular carcinoma." Hepatogastroenterology 48(37): 8-14.
Lencioni, R., C. Della Pina, et al. (2005). "Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma." Abdom Imaging 30(4): 401-408.
Lencioni, R. and J. M. Llovet (2010). "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma." Semin Liver Dis 30(1): 52-60. Lencioni, R. A., H. P. Allgaier, et al. (2003). "Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection." Radiology 228(1): 235-240.
Lin, S. M., C. J. Lin, et al. (2004). "Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm." Gastroenterology 127(6): 1714-1723.
Lin, S. M., C. J. Lin, et al. (2005). "Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less." Gut 54(8): 1151-1156.
Livraghi, T. (2009). "Single HCC smaller than 2 cm: surgery or ablation : Interventional oncologist's perspective." J Hepatobiliary Pancreat Surg.
Livraghi, T., S. N. Goldberg, et al. (2000). "Hepatocellular carcinoma: radio- frequency ablation of medium and large lesions." Radiology 214(3): 761-768. Llovet, J. M., C. Bru, et al. (1999). "Prognosis of hepatocellular carcinoma: the BCLC staging classification." Semin Liver Dis 19(3): 329-338.
Llovet, J. M., M. I. Real, et al. (2002). "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial." Lancet 359(9319): 1734-1739.
Lo, C. M., H. Ngan, et al. (2002). "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma." Hepatology 35(5): 1164-1171.
Madoff, D. C., S. Gupta, et al. (2006). "Update on the management of neuroendocrine hepatic metastases." J Vasc Interv Radiol 17(8): 1235-1249; quiz 1250.
Marelli, L., R. Stigliano, et al. (2006). "Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies." Cancer Treat Rev 32(8): 594-606.
Marrero, J. A., R. J. Fontana, et al. (2005). "Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort." Hepatology 41(4): 707-716.
McStay, M. K., D. Maudgil, et al. (2005). "Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy." Radiology 237(2): 718-726.
Modlin, I. M., M. Kidd, et al. (2005). "Current status of gastrointestinal carcinoids." Gastroenterology 128(6): 1717-1751.
Modlin, I. M. and A. Sandor (1997). "An analysis of 8305 cases of carcinoid tumors." Cancer 79(4): 813-829.
Moertel, C. G., C. M. Johnson, et al. (1994). "The management of patients with advanced carcinoid tumors and islet cell carcinomas." Ann Intern Med 120(4): 302-309.
Murthy, R., R. Nunez, et al. (2005). "Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications." Radiographics 25 Suppl 1: S41-55.
Musunuru, S., H. Chen, et al. (2006). "Metastatic neuroendocrine hepatic tumors: resection improves survival." Arch Surg 141(10): 1000-1004; discussion 1005.
Nave, H., E. Mossinger, et al. (2001). "Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years." Surgery 129(2): 170-175.
Norton, J. A. (2005). "Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases." Best Pract Res Clin Gastroenterol 19(4): 577-583.
Norton, J. A. and R. K. Kerlan (2003). "Hepatic artery embolization for treatment of patients with metastatic carcinoid tumors: a commentary." Cancer J 9(4): 241-243.
Oberg, K. (1999). "Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment." Ann Oncol 10 Suppl 2: S3-8.
Oberg, K. (2002). "Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment." Curr Opin Oncol 14(1): 38-45.
Oken, M. M., R. H. Creech, et al. (1982). "Toxicity and response criteria of the Eastern Cooperative Oncology Group." Am J Clin Oncol 5(6): 649-655.
Osborne, D. A., E. E. Zervos, et al. (2006). "Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors." Ann Surg Oncol 13(4): 572-581.
Paprottka, P. M., T. F. Jakobs, et al. "Practical Vascular Anatomy in the Preparation of Radioembolization." Cardiovasc Intervent Radiol.
Parkin, D. M., F. Bray, et al. (2001). "Estimating the world cancer burden: Globocan 2000." Int J Cancer 94(2): 153-156.
Poon, R. T., S. T. Fan, et al. (2002). "Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective." Ann Surg 235(4): 466-486.
Que, F. G., D. M. Nagorney, et al. (1995). "Hepatic resection for metastatic neuroendocrine carcinomas." Am J Surg 169(1): 36-42; discussion 42-33. Reddy, P. S., K. D. Burroughs, et al. (2007). "Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers." J Natl Cancer Inst 99(21): 1623-1633.
Rossi, S., F. Garbagnati, et al. (2000). "Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply." Radiology 217(1): 119-126.
Ruszniewski, P. and D. Malka (2000). "Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors." Digestion 62 Suppl 1: 79-83.
Safford, S. D., R. E. Coleman, et al. (2004). "Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients." Cancer 101(9): 1987-1993.
Salem, R. and K. G. Thurston (2006). "Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction." J Vasc Interv Radiol 17(10): 1571-1593.
Samlowski, W. E., H. J. Eyre, et al. (1986). "Evaluation of the response of unresectable carcinoid tumors to radiotherapy." Int J Radiat Oncol Biol Phys 12(3): 301-305.
Sarmiento, J. M. and F. G. Que (2003). "Hepatic surgery for metastases from neuroendocrine tumors." Surg Oncol Clin N Am 12(1): 231-242.
Schupak, K. D. and K. E. Wallner (1991). "The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors." Int J Radiat Oncol Biol Phys 20(3): 489-495.
Sherman, M. (2010). "Epidemiology of hepatocellular carcinoma." Oncology 78 Suppl 1: 7-10.
Shiina, S., T. Teratani, et al. (2005). "A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma." Gastroenterology 129(1): 122-130.
Soreide, O., T. Berstad, et al. (1992). "Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors." Surgery 111(1): 48-54. Therasse, E., F. Breittmayer, et al. (1993). "Transcatheter chemoembolization of progressive carcinoid liver metastasis." Radiology 189(2): 541-547.
Veenendaal, L. M., I. H. Borel Rinkes, et al. (2006). "Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy." World J Surg Oncol 4: 35.
Veltri, A., P. Moretto, et al. (2006). "Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)." Eur Radiol 16(3): 661-669.
Vetter, D., J. J. Wenger, et al. (1991). "Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients." Hepatology 13(3): 427-433. Wang, J. H., C. C. Wang, et al. (2011). "Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma." J Hepatol.
Yamakado, K., A. Nakatsuka, et al. (2002). "Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology." J Vasc Interv Radiol 13(12): 1225-1232.
Yao, K. A., M. S. Talamonti, et al. (2001). "Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors." Surgery 130(4): 677-682; discussion 682-675.
Zhang, L., W. J. Fan, et al. (2009). "Comprehensive sequential interventional therapy for hepatocellular carcinoma." Chin Med J (Engl) 122(19): 2292-2298.